These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 27280602)

  • 1. Correction: Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model.
    Fullen DJ; Noulin N; Catchpole A; Fathi H; Murray EJ; Mann A; Eze K; Balaratnam G; Borley DW; Gilbert A; Lambkin-Williams R
    PLoS One; 2016; 11(6):e0157211. PubMed ID: 27280602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction: Split inactivated COBRA vaccine elicits protective antibodies against H1N1 and H3N2 influenza viruses.
    Allen JD; Ray S; Ross TM
    PLoS One; 2018; 13(12):e0210043. PubMed ID: 30589902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction: Microneutralization Assay Titres Correlate with Protection against Seasonal Influenza H1N1 and H3N2 in Children.
    Verschoor CP; Singh P; Russell ML; Bowdish DM; Brewer A; Cyr L; Ward BJ; Loeb M
    PLoS One; 2016; 11(9):e0163830. PubMed ID: 27658259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination-challenge studies with a Port Chalmers/73 (H3N2)-based swine influenza virus vaccine: Reflections on vaccine strain updates and on the vaccine potency test.
    De Vleeschauwer A; Qiu Y; Van Reeth K
    Vaccine; 2015 May; 33(20):2360-6. PubMed ID: 25804707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective efficacy in mice of monovalent and trivalent live attenuated influenza vaccines in the background of cold-adapted A/X-31 and B/Lee/40 donor strains.
    Jang YH; Lee EY; Byun YH; Jung EJ; Lee YJ; Lee YH; Lee KH; Lee J; Seong BL
    Vaccine; 2014 Jan; 32(5):535-43. PubMed ID: 24342248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterosubtypic protection conferred by the human monoclonal antibody PN-SIA28 against influenza A virus lethal infections in mice.
    Retamal M; Abed Y; Rhéaume C; Cappelletti F; Clementi N; Mancini N; Clementi M; Burioni R; Boivin G
    Antimicrob Agents Chemother; 2015 May; 59(5):2647-53. PubMed ID: 25691648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant adenovirus encoding the HA gene from swine H3N2 influenza virus partially protects mice from challenge with heterologous virus: A/HK/1/68 (H3N2).
    Tang M; Harp JA; Wesley RD
    Arch Virol; 2002 Nov; 147(11):2125-41. PubMed ID: 12417948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction: Repurposed Transcriptomic Data Reveal Small Viral RNA Produced by Influenza Virus during Infection in Mice.
    Koire A; Gilbert BE; Sucgang R; Zechiedrich L
    PLoS One; 2017; 12(12):e0189384. PubMed ID: 29206873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies cross-reactive to influenza A (H3N2) variant virus and impact of 2010-11 seasonal influenza vaccine on cross-reactive antibodies - United States.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Apr; 61(14):237-41. PubMed ID: 22495226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines.
    Ann J; Samant M; Rheaume C; Dumas C; Beaulieu E; Morasse A; Mallett C; Hamelin ME; Papadopoulou B; Boivin G
    Vaccine; 2014 Sep; 32(43):5730-9. PubMed ID: 25173481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction: Surveillance of Influenza A Virus and Its Subtypes in Migratory Wild Birds of Nepal.
    Karmacharya D; Manandhar S; Sharma A; Bhatta T; Adhikari P; Sherchan AM; Shrestha B; Bista M; Rajbhandari R; Oberoi M; Bisht K; Hero JM; Dissanayake R; Dhakal M; Hughes J; Debnath N
    PLoS One; 2019; 14(6):e0218344. PubMed ID: 31170260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of DIVA (differentiation of infected from vaccinated animals) vaccines utilizing heterologous NA and NS1 protein strategies for the control of triple reassortant H3N2 influenza in turkeys.
    Wang L; Qin Z; Pantin-Jackwood M; Faulkner O; Suarez DL; Garcia M; Lupiani B; Reddy SM; Saif YM; Lee CW
    Vaccine; 2011 Oct; 29(45):7966-74. PubMed ID: 21907751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection of guinea pigs by vaccination with a recombinant swinepox virus co-expressing HA1 genes of swine H1N1 and H3N2 influenza viruses.
    Xu J; Yang D; Huang D; Xu J; Liu S; Lin H; Zhu H; Liu B; Lu C
    Arch Virol; 2013 Mar; 158(3):629-37. PubMed ID: 23135159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with NS1-truncated H3N2 swine influenza virus primes T cells and confers cross-protection against an H1N1 heterosubtypic challenge in pigs.
    Kappes MA; Sandbulte MR; Platt R; Wang C; Lager KM; Henningson JN; Lorusso A; Vincent AL; Loving CL; Roth JA; Kehrli ME
    Vaccine; 2012 Jan; 30(2):280-8. PubMed ID: 22067263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a human monoclonal Fab with neutralizing activity against H3N2 influenza A strain from a newly constructed human Fab library.
    Shibuya T; Yamashiro T; Masaike Y; Ohuchi M; Uechi G; Nishizono A
    Microbiol Immunol; 2008 Mar; 52(3):162-70. PubMed ID: 18402598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A comparative study of the protective properties of live recombinant and inactivated influenza vaccines made from strain A/Philippines/2/82 (H3N2) in 8- to 15-year-old children].
    Burtseva EI; Obrosova-Serova NP; Govorkova EA; Rudenko LG; Vartanian RV; Beliaev AL; Ivanova VT; Musina MD; Cheshek SG; Zazimko LA
    Vopr Virusol; 1991; 36(5):375-7. PubMed ID: 1803767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of swine influenza A virus vaccines against an H3N2 virus variant.
    Lee JH; Gramer MR; Joo HS
    Can J Vet Res; 2007 Jul; 71(3):207-12. PubMed ID: 17695596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit.
    Tamura S; Ito Y; Asanuma H; Hirabayashi Y; Suzuki Y; Nagamine T; Aizawa C; Kurata T
    J Immunol; 1992 Aug; 149(3):981-8. PubMed ID: 1634780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones.
    He W; Mullarkey CE; Duty JA; Moran TM; Palese P; Miller MS
    J Virol; 2015 Apr; 89(7):3610-8. PubMed ID: 25589655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surveillance of influenza in Houston, Texas, USA: gradual transition from A/Victoria/75 (H3N2) to A/Texas/77 (H3N2) predominance and antigenic characterization of "intermediate" strains.
    Velazco JG; Couch RB; Six HR; Glezen WP
    Bull World Health Organ; 1983; 61(2):345-52. PubMed ID: 6190585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.